We are live on ! Find out more
PBM

Propel Bio Management Portfolio holdings

AUM $191M Turnover 36.59%
1-Year Est. Return 102.42%
This Fund
S&P 500
This Quarter Est. Return
+0.98%
1 Year Est. Return
+102.42%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$86.1M
AUM Growth
-$14.6M
Cap. Flow
-$9.23M
Cap. Flow %
-10.72%
Top 10 Hldgs %
91.73%
Holding
23
New
2
Increased
4
Reduced
2
Closed
5
Avg Time Held
0.9 years
Top 10 Avg Time Held
0.9 years
Top 20 Avg Time Held
0.8 years

Top Buys

Rank Stock Value
1
MIST icon
Milestone Pharmaceuticals
MIST
+$2.89M
2
DCTH icon
Delcath Systems
DCTH
+$2.28M
3
APLT icon
Applied Therapeutics
APLT
+$983K
4
PHAT icon
Phathom Pharmaceuticals
PHAT
+$880K
5
CMPX icon
Compass Therapeutics
CMPX
+$607K

Top Sells

Rank Stock Value
1
AKRO icon
Akero Therapeutics
AKRO
+$4.87M
2
ARDX icon
Ardelyx
ARDX
+$4.82M
3
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$4.27M
4
KYMR icon
Kymera Therapeutics
KYMR
+$2.27M
5
KURA icon
Kura Oncology
KURA
+$1.13M

Sector Composition

Rank Sector Weight
1 Healthcare 67.17%
2 Energy 31.57%
3 Miscellaneous 1.25%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
PAGP icon
1
Plains GP Holdings
PAGP
$5.37B
$27.2M 31.57%
1,272,360
– –
2024 Q2
3 quarters
MDGL icon
2
Madrigal Pharmaceuticals
MDGL
$10.6B
$9.95M 11.56%
30,032
-13,000
-30% -$4.27M
2023 Q4
5 quarters
AKRO icon
3
DELISTED
Akero Therapeutics
AKRO
$9.27M 10.76%
228,884
-114,845
-33% -$4.87M
2023 Q4
5 quarters
PHAT icon
4
Phathom Pharmaceuticals
PHAT
$599M
$7.12M 8.27%
1,134,927
+145,000
+15% +$880K
2023 Q4
5 quarters
ACHV icon
5
Achieve Life Sciences
ACHV
$722M
$6.55M 7.61%
2,453,092
– –
2024 Q1
4 quarters
APLT icon
6
DELISTED
Applied Therapeutics
APLT
$5.52M 6.41%
11,285,420
+1,670,000
+17% +$983K
2023 Q4
5 quarters
RNAM
7
DELISTED
Avidity Biosciences
RNAM
$5.27M 6.12%
178,500
– –
2023 Q4
5 quarters
ABEO icon
8
Abeona Therapeutics
ABEO
$249M
$2.97M 3.45%
624,022
– –
2024 Q2
3 quarters
TCRX icon
9
TScan Therapeutics
TCRX
$14.3M
$2.88M 3.35%
2,087,139
– –
2023 Q4
5 quarters
DCTH icon
10
Delcath Systems
DCTH
$511M
$2.26M 2.63%
177,600
+160,600
+945% +$2.28M
2024 Q4
1 quarter
SNDX icon
11
Syndax Pharmaceuticals
SNDX
$1.21B
$2.25M 2.62%
183,259
– –
2024 Q1
4 quarters
ZVRA icon
12
Zevra Therapeutics
ZVRA
$607M
$1.35M 1.57%
179,874
– –
2024 Q3
2 quarters
MIST icon
13
Milestone Pharmaceuticals
MIST
$98.1M
$1.16M 1.35%
+1,451,557
New +$2.89M
2025 Q1
0 quarters
CMPX icon
14
Compass Therapeutics
CMPX
$158M
$434K 0.5%
+228,317
New +$607K
2025 Q1
0 quarters
LONA icon
15
LeonaBio Inc
LONA
$50.8M
$425K 0.49%
149,279
– –
2023 Q4
5 quarters
EIGR
16
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$423K 0.49%
146,381
– –
2023 Q4
5 quarters
ARDX icon
17
Ardelyx
ARDX
$824M
– –
-950,947
Closed -$4.82M –
CMPS icon
18
Compass Pathways
CMPS
$1.56B
– –
-25,209
Closed -$95.3K –
JSPR icon
19
Jasper Therapeutics
JSPR
$16.7M
– –
-20,000
Closed -$428K –
KURA icon
20
Kura Oncology
KURA
$855M
– –
-130,000
Closed -$1.13M –
KYMR icon
21
Kymera Therapeutics
KYMR
$8.88B
– –
-56,359
Closed -$2.27M –

Similar funds

CFG
Capital Financial Group Greenwood Village, Colorado $191M AUM
MWM
Magnolia Wealth Management Dothan, Alabama $191M AUM 17.58% 1-Year Est. Return
ALWM
Andrews Lucia Wealth Management Danville, California $191M AUM 24.94% 1-Year Est. Return
PFA
Pillar Financial Advisors Louisville, Kentucky $191M AUM 21.21% 1-Year Est. Return
NWM
Navigoe Wealth Management Redondo Beach, California $191M AUM 25.21% 1-Year Est. Return
MCA
Martin Capital Advisors San Antonio, Texas $191M AUM 42.42% 1-Year Est. Return
EMCIP
Ewing Morris & Co Investment Partners Toronto, Ontario, Canada $191M AUM 23.88% 1-Year Est. Return
HPM
H. Partners Management New York $191M AUM 5.95% 1-Year Est. Return

Propel Bio Management's Q1 2025 Portfolio in Review

As of Q1 2025, Propel Bio Management held 23 positions worth $86.1M, down 15% from $101M the previous quarter. Its ten largest holdings account for 92% of the portfolio.

Propel Bio Management withdrew a net $9.23M in Q1 2025, closing 5 positions and reducing 2 holdings. Its most notable exit was Ardelyx, an estimated $4.82M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 67% of assets, down from 77% a quarter earlier, followed by Energy and Miscellaneous.

Against the trend, Propel Bio Management opened a new position in Milestone Pharmaceuticals worth $1.16M.

  • Propel Bio Management's largest Q1 2025 buy was Milestone Pharmaceuticals: 1,451,557 shares worth $1.16M.
  • Propel Bio Management added most to Delcath Systems in Q1 2025, an estimated $2.28M increase.
  • Propel Bio Management's biggest Q1 2025 reduction was Akero Therapeutics, cutting an estimated $4.87M.
  • Propel Bio Management fully exited Ardelyx in Q1 2025, selling an estimated $4.82M.
  • Propel Bio Management's ten largest holdings make up 92% of its $86.1M portfolio in Q1 2025.
  • Propel Bio Management opened 2 new positions and closed 5 in Q1 2025.
  • Propel Bio Management's portfolio value fell 15% quarter-over-quarter to $86.1M.

Based on Propel Bio Management's 13F filing for Q1 2025, filed 15 May 2025.